Primary carnitine deficiency

Revision as of 20:17, 17 February 2015 by Vignesh Ponnusamy (talk | contribs) (→‎Treatment)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Primary carnitine deficiency
Carnitine structure.png
ICD-10 E71.3
ICD-9 277.81
OMIM 212140
DiseasesDB 31103

Template:Search infobox

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Primary carnitine deficiency is a condition that prevents the body from using fats for energy, particularly during periods without food. Carnitine, a natural substance acquired mostly through diet, is used by cells to process fats and produce energy. People with primary carnitine deficiency have defective proteins called carnitine transporters, which bring carnitine into cells and prevent its escape from the body.

Historical Perspective

The current understanding of primary carnitine deficiency has been greatly influenced by the research of Doctors Susan C. Winter and Neil Buist. Dr. Winter was one of the first doctors in the United States to begin treating inborn errors of metabolism with intravenous carnitine.


There is a decrease in the transport function as a result carnitine is lost from the body. Cells are not supplied with an adequate amount of carnitine. Without carnitine, fats cannot be processed correctly and are not converted into energy, which can lead to characteristic signs and symptoms of this disorder.


Mutations in the SLC22A5 gene lead to the production of defective carnitine transporters. This condition is inherited in an autosomal recessive pattern.

Differentiating Primary Carnitine Deficiency from other Diseases

This condition is sometimes mistaken for Reye syndrome, a severe disorder that develops in children while they appear to be recovering from viral infections such as chickenpox or flu. Most cases of Reye syndrome are associated with the use of aspirin during these viral infections.

Epidemiology and Demographics

On the average, primary carnitine deficiency affects 1 in every 40,000 live births in Japan and 1 in every 37,000 to 100,000 newborns in Australia. The incidence of this condition in other populations is unknown, but is probably similar to that reported for Japan.

Risk Factors

Natural History, Complications and Prognosis

Serious complications such as heart failure, liver problems, coma, and sudden unexpected death can occur. Acute illness due to primary carnitine deficiency can be triggered by periods of fasting or illnesses such as viral infections, particularly when eating is reduced.



Physical Examination

Typically, initial signs of this disorder occur during infancy or early childhood and often include brain function abnormalities



Laboratory Findings

Electrolyte and Biomarker Studies


Primary carnitine deficiency is sometimes diagnosed in adults and is then thought to be less severe both in symptoms and life expectation. Treatment is usually done by supplementation of L-carnitine after assessing the severity of the deficiency after a muscular biopsy.

Contraindicated medications

Carnitine deficiency is considered an absolute contraindication to the use of the following medications:


This article incorporates public domain text from The U.S. National Library of Medicine

Template:Endocrine, nutritional and metabolic pathology

Template:WikiDoc Sources